Angina Pectoris Drugs Market 2027 by Therapeutic and Geography | The Insight Partners

Angina Pectoris Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Therapeutic Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets, Other) and Geography

Report Code: TIPRE00008008 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Angina pectoris is a heart condition, which causes chest pain due to coronary heart disease. The situation occurs when the supply of blood is not adequate to the heart. This condition causes pressure, fullness, and pain in the center of the chest. One of the most common causes is the narrowing of coronary arteries, resulting in less supply of blood and oxygen to the heart muscles. The condition is not a heart attack but increases the risk of heart attack for the future. Angina pectoris can be treated by using medication, Angioplasty and vascular stenting, and Coronary artery bypass graft surgery.

MARKET DYNAMICS

The angina pectoris drugs market is anticipated to grow in the forecast period. Increasing lifestyle diseases such as diabetes high cholesterol, cancer, among other chronic diseases, are significant factors resulting in associated cardiovascular diseases worldwide. For instance, 17.9 million people die every year due to CVDs, accounting for 31% of worldwide deaths, the WHO. Moreover, increasing cases of heart diseases are also increasing the chances of angina pectoris. In the U.S., approximately 647,000 Americans die from heart diseases every year, the CDC. Moreover, increasing drug approvals are propelling the growth of the market. For instance, recently, in 2019, Glenmark Pharmaceuticals received approval from the FDA for Ranolazine. It is a generic version of Gilead Sciences.

MARKET SCOPE

The "Global Angina Pectoris Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of angina pectoris drugs market with detailed market segmentation by therapeutic class and geography. The global angina pectoris drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading angina pectoris drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global angina pectoris drugs market is segmented on the basis of therapeutic class. Based on therapeutic class, the market is segmented as beta blockers, calcium channel blockers, nitrates, angiotensin-converting enzyme inhibitors (ACE Inhibitors), anti-platelets and others.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global angina pectoris drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The angina pectoris drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting angina pectoris drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the angina pectoris drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the angina pectoris drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angina pectoris drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for angina pectoris drugs market in the global market. Below mentioned is the list of few companies engaged in the angina pectoris drugs market.

The report also includes the profiles of key angina pectoris drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Sanofi
  •  Pfizer
  •  Otsuka Pharmaceutical Co., Ltd.
  •  Novartis AG
  •  Merck & Co., Inc.
  •  Gilead Sciences, Inc.
  •  Amgen Inc.
  •  Eli Lilly and Company

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Angina Pectoris Drugs Market - By Therapeutic Class
1.3.2 Angina Pectoris Drugs Market - By Region
1.3.2.1 by Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ANGINA PECTORIS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ANGINA PECTORIS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. ANGINA PECTORIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANGINA PECTORIS DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANGINA PECTORIS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. ANGINA PECTORIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC CLASS
7.1. OVERVIEW
7.2. THERAPEUTIC CLASS MARKET FORECASTS AND ANALYSIS
7.3. BETA BLOCKERS
7.3.1. Overview
7.3.2. Beta Blockers Market Forecast and Analysis
7.4. CALCIUM CHANNEL BLOCKERS
7.4.1. Overview
7.4.2. Calcium Channel Blockers Market Forecast and Analysis
7.5. NITRATES
7.5.1. Overview
7.5.2. Nitrates Market Forecast and Analysis
7.6. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
7.6.1. Overview
7.6.2. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) Market Forecast and Analysis
7.7. ANTI-PLATELETS
7.7.1. Overview
7.7.2. Anti-Platelets Market Forecast and Analysis
7.8. OTHER
7.8.1. Overview
7.8.2. Other Market Forecast and Analysis

8. ANGINA PECTORIS DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Angina Pectoris Drugs Market Overview
8.1.2 North America Angina Pectoris Drugs Market Forecasts and Analysis
8.1.3 North America Angina Pectoris Drugs Market Forecasts and Analysis - By Therapeutic Class
8.1.4 North America Angina Pectoris Drugs Market Forecasts and Analysis - By Countries
8.1.4.1 United States Angina Pectoris Drugs Market
8.1.4.1.1 United States Angina Pectoris Drugs Market by Therapeutic Class
8.1.4.2 Canada Angina Pectoris Drugs Market
8.1.4.2.1 Canada Angina Pectoris Drugs Market by Therapeutic Class
8.1.4.3 Mexico Angina Pectoris Drugs Market
8.1.4.3.1 Mexico Angina Pectoris Drugs Market by Therapeutic Class
8.2. EUROPE
8.2.1 Europe Angina Pectoris Drugs Market Overview
8.2.2 Europe Angina Pectoris Drugs Market Forecasts and Analysis
8.2.3 Europe Angina Pectoris Drugs Market Forecasts and Analysis - By Therapeutic Class
8.2.4 Europe Angina Pectoris Drugs Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Angina Pectoris Drugs Market
8.2.4.1.1 Germany Angina Pectoris Drugs Market by Therapeutic Class
8.2.4.2 France Angina Pectoris Drugs Market
8.2.4.2.1 France Angina Pectoris Drugs Market by Therapeutic Class
8.2.4.3 Italy Angina Pectoris Drugs Market
8.2.4.3.1 Italy Angina Pectoris Drugs Market by Therapeutic Class
8.2.4.4 Spain Angina Pectoris Drugs Market
8.2.4.4.1 Spain Angina Pectoris Drugs Market by Therapeutic Class
8.2.4.5 United Kingdom Angina Pectoris Drugs Market
8.2.4.5.1 United Kingdom Angina Pectoris Drugs Market by Therapeutic Class
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Angina Pectoris Drugs Market Overview
8.3.2 Asia-Pacific Angina Pectoris Drugs Market Forecasts and Analysis
8.3.3 Asia-Pacific Angina Pectoris Drugs Market Forecasts and Analysis - By Therapeutic Class
8.3.4 Asia-Pacific Angina Pectoris Drugs Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Angina Pectoris Drugs Market
8.3.4.1.1 Australia Angina Pectoris Drugs Market by Therapeutic Class
8.3.4.2 China Angina Pectoris Drugs Market
8.3.4.2.1 China Angina Pectoris Drugs Market by Therapeutic Class
8.3.4.3 India Angina Pectoris Drugs Market
8.3.4.3.1 India Angina Pectoris Drugs Market by Therapeutic Class
8.3.4.4 Japan Angina Pectoris Drugs Market
8.3.4.4.1 Japan Angina Pectoris Drugs Market by Therapeutic Class
8.3.4.5 South Korea Angina Pectoris Drugs Market
8.3.4.5.1 South Korea Angina Pectoris Drugs Market by Therapeutic Class
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Angina Pectoris Drugs Market Overview
8.4.2 Middle East and Africa Angina Pectoris Drugs Market Forecasts and Analysis
8.4.3 Middle East and Africa Angina Pectoris Drugs Market Forecasts and Analysis - By Therapeutic Class
8.4.4 Middle East and Africa Angina Pectoris Drugs Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Angina Pectoris Drugs Market
8.4.4.1.1 South Africa Angina Pectoris Drugs Market by Therapeutic Class
8.4.4.2 Saudi Arabia Angina Pectoris Drugs Market
8.4.4.2.1 Saudi Arabia Angina Pectoris Drugs Market by Therapeutic Class
8.4.4.3 U.A.E Angina Pectoris Drugs Market
8.4.4.3.1 U.A.E Angina Pectoris Drugs Market by Therapeutic Class
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Angina Pectoris Drugs Market Overview
8.5.2 South and Central America Angina Pectoris Drugs Market Forecasts and Analysis
8.5.3 South and Central America Angina Pectoris Drugs Market Forecasts and Analysis - By Therapeutic Class
8.5.4 South and Central America Angina Pectoris Drugs Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Angina Pectoris Drugs Market
8.5.4.1.1 Brazil Angina Pectoris Drugs Market by Therapeutic Class
8.5.4.2 Argentina Angina Pectoris Drugs Market
8.5.4.2.1 Argentina Angina Pectoris Drugs Market by Therapeutic Class

9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

10. ANGINA PECTORIS DRUGS MARKET, KEY COMPANY PROFILES
10.1. SANOFI
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. PFIZER
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. OTSUKA PHARMACEUTICAL CO., LTD.
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. NOVARTIS AG
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
10.5. MERCK & CO., INC.
10.5.1. Key Facts
10.5.2. Business Description
10.5.3. Products and Services
10.5.4. Financial Overview
10.5.5. SWOT Analysis
10.5.6. Key Developments
10.6. GILEAD SCIENCES, INC.
10.6.1. Key Facts
10.6.2. Business Description
10.6.3. Products and Services
10.6.4. Financial Overview
10.6.5. SWOT Analysis
10.6.6. Key Developments
10.7. AMGEN INC.
10.7.1. Key Facts
10.7.2. Business Description
10.7.3. Products and Services
10.7.4. Financial Overview
10.7.5. SWOT Analysis
10.7.6. Key Developments
10.8. ELI LILLY AND COMPANY
10.8.1. Key Facts
10.8.2. Business Description
10.8.3. Products and Services
10.8.4. Financial Overview
10.8.5. SWOT Analysis
10.8.6. Key Developments
10.9. ASTRAZENECA
10.9.1. Key Facts
10.9.2. Business Description
10.9.3. Products and Services
10.9.4. Financial Overview
10.9.5. SWOT Analysis
10.9.6. Key Developments
10.10. GLAXOSMITHKLINE PLC.
10.10.1. Key Facts
10.10.2. Business Description
10.10.3. Products and Services
10.10.4. Financial Overview
10.10.5. SWOT Analysis
10.10.6. Key Developments

11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
The List of Companies

1. Sanofi
2. Pfizer
3. Otsuka Pharmaceutical Co., Ltd.
4. Novartis AG
5. Merck & Co., Inc.
6. Gilead Sciences, Inc.
7. Amgen Inc.
8. Eli Lilly and Company
TIPRE00008008
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking